Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Stock Information for Sonoma Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering
Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart
Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.